

# Todd Aguilera

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4183674/publications.pdf>

Version: 2024-02-01

27  
papers

2,764  
citations

623734

14  
h-index

526287

27  
g-index

29  
all docs

29  
docs citations

29  
times ranked

4627  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mammalian Expression of Infrared Fluorescent Proteins Engineered from a Bacterial Phytochrome. <i>Science</i> , 2009, 324, 804-807.	12.6	638
2	Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 4311-4316.	7.1	524
3	Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 4317-4322.	7.1	454
4	Autofluorescent Proteins with Excitation in the Optical Window for Intravital Imaging in Mammals. <i>Chemistry and Biology</i> , 2009, 16, 1169-1179.	6.0	244
5	Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. <i>Nature Cell Biology</i> , 2016, 18, 1078-1089.	10.3	203
6	Early-Stage Non-Small Cell Lung Cancer: Quantitative Imaging Characteristics of <sup>18</sup> F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis. <i>Radiology</i> , 2016, 281, 270-278.	7.3	152
7	Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. <i>Journal of Clinical Investigation</i> , 2019, 129, 5553-5567.	8.2	94
8	Fast <sup>18</sup> F Labeling of a Near-Infrared Fluorophore Enables Positron Emission Tomography and Optical Imaging of Sentinel Lymph Nodes. <i>Bioconjugate Chemistry</i> , 2010, 21, 1811-1819.	3.6	78
9	Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 2652.	3.7	71
10	Parallel in Vivo and in Vitro Selection Using Phage Display Identifies Protease-dependent Tumor-targeting Peptides. <i>Journal of Biological Chemistry</i> , 2010, 285, 22532-22541.	3.4	63
11	Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion: A New Role for the AXL Receptor Tyrosine Kinase. <i>Clinical Cancer Research</i> , 2017, 23, 2928-2933.	7.0	59
12	Macrophages Promote Circulating Tumor Cell-Mediated Local Recurrence following Radiotherapy in Immunosuppressed Patients. <i>Cancer Research</i> , 2018, 78, 4241-4252.	0.9	36
13	The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. <i>British Journal of Radiology</i> , 2019, 92, 20180228.	2.2	35
14	A 3-D Riesz-Covariance Texture Model for Prediction of Nodule Recurrence in Lung CT. <i>IEEE Transactions on Medical Imaging</i> , 2016, 35, 2620-2630.	8.9	31
15	Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1399-1400.	0.8	16
16	Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage III Pancreatic Adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1292-1300.	4.9	15
17	Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations. <i>Clinical Cancer Research</i> , 2020, 26, 2972-2985.	7.0	9
18	Racial Disparities in Time to Treatment Initiation and Outcomes for Early Stage Anal Squamous Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 762-769.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Recent Trends and Overall Survival of Young Versus Older Adults With Stage II to III Rectal Cancer Treated With and Without Surgery in the United States, 2010-2015. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 694-700.	1.3	5
20	Targeting TAM to Tame Pancreatic Cancer. Targeted Oncology, 2020, 15, 579-588.	3.6	4
21	Stage-specific Conditional Survival Among Young (Age Below 50%) Versus Older (Age 50% and Above) Adults With Colorectal Cancer in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 526-530.	1.3	4
22	The End of the Hypoxic EPOch. International Journal of Radiation Oncology Biology Physics, 2015, 91, 895-897.	0.8	3
23	Patterns of Care for Stage II-III Rectosigmoid Cancers in the United States, 2004-2015. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 311-318.	1.3	3
24	Disparities in Characteristics, Access to Care, and Oncologic Outcomes in Young-Onset Colorectal Cancer at a Safety-Net Hospital. JCO Oncology Practice, 2021, 17, e614-e622.	2.9	3
25	Feasibility and Outcome of Routine Use of Concurrent Chemoradiation in HIV-positive Patients With Squamous Cell Anal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 701-708.	1.3	2
26	Trends in Primary Surgical Resection and Chemotherapy for Metastatic Colorectal Cancer, 2000-2016. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 850-856.	1.3	2
27	Patterns of Dose Escalation Among Patients With Esophageal Cancer Undergoing Definitive Radiation Therapy: 2006-2016. Advances in Radiation Oncology, 2021, 6, 100580.	1.2	0